Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic insights and therapeutic efficacy of PARP inhibitors in a high-LOH patient-derived xenograft from malignant transformation of ovarian teratoma.

Biochemical and biophysical research communications - 15 Dec 2025

Nakagawa Atsushi, Tamauchi Satoshi, Xinyuan Wang, Yoshida Kosuke, Yokoi Akira, Yoshikawa Nobuhisa, Niimi Kaoru, Kajiyama Hiroaki

Abstract excerpt

The malignant transformation of ovarian mature cystic teratoma (MTMCT) is a rare and aggressive condition often diagnosed at advanced stages with limited treatment options. Leveraging cancer genomic profiling (CGP), this study evaluated the efficacy of poly(ADP-ribose) polymerase (PARP) inhibitors in a patient-derived xenograft (PDX) model of MTMCT with high loss of heterozygosity (LOH). Tumor samples from a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases
Share to Cell Transformation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomic Instability

Share to Loss of Heterozygosity

Share to Ovarian Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Teratoma

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 41242305
DOI: 10.1016/j.bbrc.2025.152979

Genes

EMSY
STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic insights and therapeutic efficacy of PARP inhibitors in a high-LOH patient-derived xenograft from malignant transformation of ovarian teratoma.PMID 41242305Read ↗

Genomic profiling of meiotic errors and early malignant transformation events in ovarian mature teratoma.Semantic proximity Read ↗

Multi-region exome sequencing of ovarian teratomas reveals 2N near-diploid genomes, paucity of somatic mutations, and extensive allelic imbalances shared across mature, immature, and disseminated componentsSemantic proximity Read ↗

Genomic analysis of patient-derived xenograft models reveals intra-tumor heterogeneity in endometrial cancer and can predict tumor growth inhibition with talazoparibSemantic proximity Read ↗

Multiregion exome sequencing of ovarian immature teratomas reveals 2N near-diploid genomes, paucity of somatic mutations, and extensive allelic imbalances shared across mature, immature, and disseminated components.Semantic proximity Read ↗

Updates in the Management of Malignant Ovarian Germ Cell TumorsSemantic proximity Read ↗

The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma.Semantic proximity Read ↗

Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell LinesSemantic proximity Read ↗

Biology-driven therapy advances in high-grade serous ovarian cancerSemantic proximity Read ↗

Clinically actionable genomic and transcriptomic landscape of advanced neuroendocrine neoplasms.Semantic proximity Read ↗

Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical responseSemantic proximity Read ↗

Analysis of the genomic landscape of yolk sac tumors reveals mechanisms of evolution and chemoresistance.Semantic proximity Read ↗

Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.